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Introduction
Chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are 2 severe 
pulmonary disorders characterized by quite distinct clinical and pathological features, manifesting as 
alveolar emphysema and bronchiolar inflammation in COPD, versus interstitial fibrosis and honey-
combing in IPF (1–3). The pathogenesis of  COPD and IPF remain incompletely understood. COPD 
is associated with a characteristic pattern of  chronic inflammation with increased numbers of  neutro-
phils in the airway lumen and increased numbers of  macrophages and T and B lymphocytes, though 
it remains to be clearly defined how this inflammation relates to clinical outcomes and disease pro-
gression (4). While inflammation had classically been anticipated to precede fibrosis in IPF, the failure 
of  immunosuppressive therapies has led to a shift in thinking, whereby the disease is now considered 
to arise in genetically susceptible individuals as a consequence of  aberrant wound healing following 
repetitive alveolar injury (5). Nonetheless, it is anticipated that there are a number of  similarities in the 
etiologies and pathogenesis of  the 2 disorders, whereby an accelerated pulmonary senescence coupled 
with the long-term exposure to noxious chemical agents culminates in chronic, progressive diseases 
characterized by a compromised regenerative capacity (3, 6–8). The divergences in tissue renewal pro-
cesses between the 2 diseases ultimately then give rise to the distinct pathologies observed. Effective 
treatments are lacking for both COPD and IPF, in part due to our still-limited understanding of  the 
The neutrophil chemoattractant proline-glycine-proline (PGP) is generated from collagen by 
matrix metalloproteinase-8/9 (MMP-8/9) and prolyl endopeptidase (PE), and it is concomitantly 
degraded by extracellular leukotriene A4 hydrolase (LTA4H) to limit neutrophilia. Components of 
cigarette smoke can acetylate PGP, yielding a species (AcPGP) that is resistant to LTA4H-mediated 
degradation and can, thus, support a sustained neutrophilia. In this study, we sought to elucidate 
if an antiinflammatory system existed to degrade AcPGP that is analogous to the PGP-LTA4H 
axis. We demonstrate that AcPGP is degraded through a previously unidentified action of the 
enzyme angiotensin-converting enzyme (ACE). Pulmonary ACE is elevated during episodes of 
acute inflammation, as a consequence of enhanced vascular permeability, to ensure the efficient 
degradation of AcPGP. Conversely, we suggest that this pathway is aberrant in chronic obstructive 
pulmonary disease (COPD) enabling the accumulation of AcPGP. Consequently, we identify 
a potentially novel protective role for AcPGP in limiting pulmonary fibrosis and suggest the 
pathogenic function attributed to ACE in idiopathic pulmonary fibrosis (IPF) to be a consequence of 
overzealous AcPGP degradation. Thus, AcPGP seemingly has very divergent roles: it is pathogenic in 
its capacity to drive neutrophilic inflammation and matrix degradation in the context of COPD, but it 
is protective in its capacity to limit fibrosis in IPF.
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mechanisms defining disease progression. Accordingly, a variety of  underlying pathogenic mecha-
nisms are being explored, including oxidative stress, protease/antiprotease imbalance, and aberrant 
repair and remodeling processes (9–11).
A protease/antiprotease imbalance is a hallmark of  many chronic lung diseases, with proteases tar-
geting components of  the extracellular matrix (ECM) for degradation, disrupting tissue architecture and 
releasing ECM-derived bioactive signals, termed matrikines, that can perpetuate inflammation (12, 13). 
The tripeptide proline-glycine-proline (PGP) is one such matrikine, being a neutrophil chemoattractant 
derived from ECM collagen that exerts its activity by mimicking key sequences found in ELR+ chemokines 
and binding to CXCR1/2 (14). PGP is generated from collagen via the sequential enzymatic activity of  
matrix metalloproteinases (MMP; with key roles established for MMP-1, -8, and -9) and prolyl endopep-
tidase (PE) (15). Since neutrophils are a source of  the proteases that generate PGP, it is anticipated that 
this pathway can drive a self-sustaining cycle of  neutrophilic inflammation (16). PGP can subsequently be 
chemically acetylated on its N-terminus (AcPGP), which functions to enhance its chemotactic potential 
(17–19). Significant quantities of  PGP and AcPGP are found in patients with chronic neutrophilic lung 
diseases such as COPD, cystic fibrosis (CF), and bronchiolitis obliterans syndrome (BOS), peaking with 
exacerbations of  disease and, in some instances, inversely correlating with lung function (14, 15, 20–24).
Recently, we identified an antiinflammatory pathway whereby PGP is degraded during episodes of  
acute neutrophilic inflammation by the extracellular activity of  the enzyme leukotriene A4 hydrolase 
(LTA4H) (17) and showed this degradation to be critical to the timely resolution of  inflammation (25). 
LTA4H classically functions intracellularly to catalyze the generation of  the proinflammatory lipid media-
tor leukotriene B4 (LTB4) (26, 27). LTB4 can drive the recruitment and activation of  an array of  cells, includ-
ing neutrophils, and is implicated in protection against invading microorganisms, but also in the pathology 
of  multiple diseases (28). Therefore, LTA4H represents a highly unusual enzyme with directly opposing 
pro- and antiinflammatory activities that dictate the amplitude and persistence of  neutrophilic inflamma-
tion (29). We have subsequently demonstrated that this LTA4H-mediated PGP degradation is perturbed by 
cigarette smoke, contributing to the accumulation of  PGP in COPD (17, 21).
While PGP is readily broken down via LTA4H, AcPGP is completely protected from degradation (17), 
and thus, the acetylation process is seemingly a key event in driving the pathogenesis of  aforementioned 
disease states. Accordingly, there has been a sharper focus on processes that define the bioavailability of  the 
acetylated form of  PGP. Acetylation of  peptides is classically the function of  N-acetyl transferases; however, 
the small size and N-terminal proline of  PGP seemingly preclude it from being a favorable substrate for such 
enzymes (30, 31). Subsequently, however, we have demonstrated that PGP can be chemically acetylated to 
AcPGP through the action of  reactive aldehydes, such as acrolein and acetaldehyde, present in cigarette 
smoke (18). Reactive aldehydes can also be generated physiologically during episodes of  severe inflamma-
tion, with acrolein, for example, being a product of  lipid peroxidation and the myeloperoxidase- catalyzed 
(MPO-catalyzed) oxidation of  threonine (32, 33). While the processes of  PGP acetylation are increasingly 
being elucidated, it is still unknown as to whether there is an antiinflammatory system in place to degrade 
AcPGP that is analogous to the PGP-LTA4H axis. We previously demonstrated that AcPGP was completely 
protected from degradation by LTA4H but that bronchoalveolar lavage fluid (BALF) from influenza-infected 
mice possessed some capacity to degrade AcPGP (17). Although this AcPGP-degrading activity was signifi-
cantly inferior to the capacity of  the BALF to degrade PGP (17), the likely disproportionate generation of  
PGP versus AcPGP and the superior chemotactic activity of  the acetylated peptide may seeming make this 
AcPGP-degrading activity physiologically relevant.
In this study, we looked to characterize and identify the source of  this AcPGP-degrading activity and 
demonstrated that the enzyme responsible was angiotensin-converting enzyme (ACE). Moreover, we reveal 
how ACE functions during inflammation, in conjunction with LTA4H, to ensure efficient resolution of  the 
PGP/AcPGP pathway. Furthermore, we demonstrate that this ACE pathway may be differentially aber-
rant in COPD versus IPF in a manner that will define the divergent pathogenesis of  these disease states.
Results
A potentially novel role for the enzyme ACE in degrading AcPGP. Having previously ascertained that the BALF 
of  influenza-infected mice possessed a modest capacity to degrade AcPGP, we looked to determine the 
levels and tissue distribution of  this potentially novel activity in naive animals. An AcPGP-degrading 
activity was particularly prevalent in collagen-rich tissues of  the lung and intestine (Figure 1A). In order 
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for such an enzymatic activity to be functionally relevant, however, it must be present in an extracellular 
environment to gain access to AcPGP, and thus, activity of  BALF and serum of  naive mice was also deter-
mined. While weak AcPGP-degrading activity was detectable in naive BALF, it was substantially greater 
within serum (Figure 1B); therefore, it was deemed that serum was an appropriate matrix from which to 
further characterize and identify this activity. The capacity of  naive serum to degrade AcPGP over time 
was further interrogated by measuring loss of  the peptide by mass spectrometry (Figure 1C) and the cor-
responding release of  free proline via reaction with ninhydrin (Figure 1D). Serum demonstrated a robust 
capacity to cumulatively degrade AcPGP, with loss of  peptide correlating with release of  free proline. 
Importantly, serum from LTA4H-KO mice displayed a comparable capacity to degrade AcPGP to that 
Figure 1. An extracellular enzymatic activity that degrades AcPGP. Tissue homogenates (A) or BALF and serum (B) from naive Balb/c mice were incubated 
with AcPGP, and degradation was assessed after 24 hours by mass spectrometry. (C and D) Serum from naive lta4h–/–
 
mice and littermate controls was 
incubated with AcPGP and degradation assessed at multiple time points by mass spectrometry (C) or release of free proline (D). Serum from naive Balb/c 
mice was heat inactivated (HI) for 10 min at 100°C (E) or preincubated with selective inhibitors (all at 1 μM) for 30 min at 37°C (F) prior to incubation with 
AcPGP. Degradation of AcPGP was subsequently assessed by mass spectrometry (E and F). A and B are from 4 mice/group and representative of 3 exper-
iments. C–F are triplicates and representative of 2 independent studies. Results depicted as mean ± SEM. *P < 0.05 or **P < 0.01 using Mann–Whitney 
statistical test (A, B, and E) or Kruskal-Wallis with Dunn’s post test (F).
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Figure 2. Angiotensin-converting enzyme (ACE) degrades AcPGP. Serum from naive Balb/c mice was preincubated with multiple concentrations (rang-
ing from 1 nM to 100 μM) of captopril (A) or enalapril (B) for 30 min at 37°C prior to incubation with AcPGP and degradation of peptide was assessed 
after 24 hours by mass spectrometry. (C) Plasma from ACE-KO mice (ACE 1 = null for ACE; ACE 14/14 = null for somatic ACE; n = 14) and littermate 
controls (n = 9) were incubated at 37°C with AcPGP and degradation of peptide assessed after 24 hours by mass spectrometry. Recombinant ACE 
(0.001–0.1 U/ml) and prolidase (1 U/ml) were incubated with AcPGP and degradation assessed at multiple time points by mass spectrometry. ***P < 
0.001 (D) or release of free proline (E). (F) Recombinant human ACE was incubated with AcPGP or Mca-RPPGFSAFK(Dnp)-OH and various concentra-
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of  WT animals (Figure 1, C and D), validating that this AcPGP-degrading activity was distinct from the 
LTA4H-mediated PGP-degrading activity. Heat-inactivating serum prior to incubation with AcPGP large-
ly ablated its capacity to degrade the peptide, supportive of  this being an enzymatic activity (Figure 1E). 
Subsequently, broad-acting inhibitors were assessed for their capacity to inhibit serum-mediated AcPGP 
degradation to further define the nature of  the enzyme responsible (Figure 1F). While classical serine and 
cysteine protease inhibitors had no effect on the AcPGP-degrading activity of  serum, the activity was 
significantly reduced by EDTA, suggestive that the enzyme responsible was likely a metalloproteinase.
While there was clearly an AcPGP-degrading metalloprotease activity that was abundant in the blood, 
the nature of  the enzyme remained unknown, with a limited number of  proteases seemingly capable of  
degrading such a small acetylated peptide. Angiotensin-1–converting enzyme (ACE, EC 3.4.15.1) is a zinc 
peptidase that is a central component of  the renin-angiotensin-aldosterone system (RAAS), wherein it 
converts angiotensin I into the vasoactive peptide hormone angiotensin II (AngII) (34, 35). However, ACE 
has also been demonstrated to be capable of  degrading a variety of  other peptides, including the acetylated 
tetrapeptide N-acetyl-Ser-Asp-Lys-Pro (AcSDKP; readily metabolizing circulating AcSDKP into inactive 
AcSD and KP; ref. 36). It was thus rationalized that ACE may be the enzyme that was degrading AcPGP, 
with this notion supported by the abundance of  activity in serum and its dependence on metal ions. To 
test this hypothesis, the capacity of  ACE-specific inhibitors, captopril and enalapril, to abrogate serum 
AcPGP–degrading activity was assessed. Both captopril (Figure 2A) and enalapril (Figure 2B) displayed 
a potent and absolute capacity to inhibit serum AcPGP–degrading activity, strongly suggesting that ACE 
was indeed the enzyme responsible. Importantly, plasma from ACE-KO mice displayed minimal capacity 
to degrade AcPGP relative to that of  littermate controls (Figure 2C), highlighting that degradation of  the 
peptide was almost entirely attributable to ACE. ACE is a dipeptidyl carboxypeptidase, and thus, we ratio-
nalized that the enzyme should cleave the GP from AcPGP. However, incubation of  serum with AcPGP 
resulted in the release of  free proline (Figure 1D), and this was abrogated if  AcPGP was substituted for 
AcPGG (data not shown), suggestive that a proline is being cleaved from the C-terminus of  AcPGP. We 
therefore hypothesized that an enzymatic cascade was present in serum, whereby AcPGP was initially 
cleaved by ACE to give rise to AcP and GP, with the GP subsequently being cleaved by prolidase into 
its individual amino acid constituents. Subsequently, the capacity of  recombinant ACE, with and without 
recombinant prolidase, to degrade AcPGP was assessed by measuring loss of  the peptide itself  by mass 
spectrometry (Figure 2D) and generation of  free proline via its reaction with ninhydrin (Figure 2E). ACE 
alone was able to potently and dose-dependently degrade AcPGP (Figure 2D); however, a concomitant 
release of  free proline also required the presence of  prolidase (Figure 2E), thus validating the hypothesized 
proteolytic cascade. We examined captopril inhibition of  ACE-mediated AcPGP degradation and found 
that the 50% inhibitory concentration (IC50) was lower than that seen for degradation of  an AngI-like ACE 
substrate (Figure 2F). Levels of  ACE in a variety of  tissues (Figure 2G) and BALF/serum (Figure 2H) of  
naive mice were assessed and shown to correlate with AcPGP-degrading activity (Figure 1, A and B). Thus, 
it appeared that ACE represented a potentially novel antiinflammatory arm of  a proteolytic cascade that 
defined the bioavailability of  PGP/AcPGP (Figure 2I).
Elevated airway ACE levels during episodes of  acute pulmonary inflammation facilitate AcPGP degradation. 
We have previously demonstrated that neutrophils are able to generate PGP via the release of  proteolytic 
enzymes that target collagen (16, 17, 25, 37). However, during episodes of  acute inflammation, there is 
the concomitant release of  LTA4H to ensure that PGP is readily degraded and inflammation efficiently 
resolved (17, 25). Since liberated PGP is free to be acetylated, which could in turn exacerbate inflamma-
tion, we hypothesized that there may also be a synchronized augmentation in BALF ACE during episodes 
of  acute pulmonary inflammation so as to degrade AcPGP generated. Mice were subsequently challenged 
with intranasal (i.n.) LPS, and at 0, 6, 12 and 24 hours after challenge, BALF AcPGP–degrading activity 
(Figure 3B) and the concentration of  ACE protein (Figure 3A) were assessed. Both BALF AcPGP–
degrading activity and levels of  ACE itself  exhibited a commensurate increase following LPS challenge 
tions of captopril. Degradation of AcPGP was assessed after 24 hours by mass spectrometry and of Mca- RPPGFSAFK(Dnp)-OH fluorometrically. Levels 
of ACE protein in tissue homogenates (G) or BALF and serum (H) from naive Balb/c mice were determined by ELISA. (I) Schematic of the proteolytic 
cascade that defines the availability of collagen-derived matrikines PGP and AcPGP. A, B, D, E, and F are triplicates and representative of 2 indepen-
dent studies. G and H are from 4 mice/group and representative of 2 experiments. Results depicted as mean ± SEM. *P < 0.05 or **P < 0.01 using 
Mann–Whitney statistical test (C and H) or Kruskal-Wallis with Dunn’s post test (G).
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Figure 3. ACE is elevated in BALF following pulmonary challenge to promote AcPGP degradation and is inhibited by captopril. (A and B) Balb/c mice 
were administered 10 μg LPS i.n. and culled after 6, 12, or 24 hours. BALF ACE protein levels were determined by ELISA (A). BALF from these mice was 
incubated with AcPGP and degradation assessed after 24 hours by mass spectrometry (B). (C–E) Naive Balb/c mice were administered histamine i.v. and 
culled after 30 min. BALF AcPGP–degrading activity was assessed by mass spectrometry (C) and ACE protein levels by ELISA (D). (E) Correlation between 
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(Figure 3, A and B). While ACE can be expressed by numerous cell types, the relative abundance of  this 
enzyme in serum led us to speculate that the increase in BALF levels with inflammation may reflect an 
escalation in vascular permeability and ensuing edema. Early changes in vascular permeability are induced 
via the direct action of  vasoactive agents, such as histamine, on endothelial cells, whereas later changes in 
vascular permeability are often imparted by the action of  neutrophils upon endothelium (38, 39). Subse-
quently, histamine was administered to mice and, after 30 minutes, resulted in an increased airway edema 
and a corresponding increase in BALF AcPGP–degrading activity (Figure 3C) and levels of  ACE (Figure 
3D), which correlated with levels of  BALF serum albumin (Figure 3E). Similarly, i.n. administration of  
neutrophil chemoattractant MIP-2 to mice resulted in augmented airway neutrophilia and an increase in 
BALF AcPGP–degrading activity (Figure 3F) and levels of  ACE (Figure 3G), which again correlated with 
levels of  BALF serum albumin (Figure 3H). Together, these results would suggest that changes in vascu-
lar permeability during periods of  inflammation may enable ACE to accumulate in the lung to facilitate 
AcPGP degradation. We subsequently questioned whether abrogation of  ACE activity during episodes 
of  acute pulmonary inflammation would enable AcPGP to accumulate in vivo. WT mice were therefore 
administered i.n. LPS with and without ACE inhibitor captopril, and BALF levels of  PGP (Figure 3I) 
and AcPGP (Figure 3J) were assessed at 24 hours after challenge. Neither PGP nor AcPGP was, however, 
detectable following LPS exposure, with or without captopril treatment. Previously, we have demonstrated 
that PGP is efficiently broken down by extracellular LTA4H during acute airway inflammation driven by 
bacterial infection (17), rationalizing the absence of  PGP in LPS-treated animals. It was deemed feasible 
that, following LPS challenge, PGP was being generated but then rapidly degraded by LTA4H, providing 
an insufficient window for AcPGP generation. LTA4H-KO mice were therefore also exposed to LPS, with 
and without captopril treatment, and BALF PGP and AcPGP were measured (Figure 3, I and J). Accord-
ingly, LPS-exposed LTA4H-KO mice displayed significant levels of  PGP in their airways at 24 hours after 
challenge (Figure 3I), and the majority of  LTA4H-KO mice that were coadministered captopril also pre-
sented with substantial quantities of  AcPGP (Figure 3J). Thus, it would seem that PGP substrate must be 
allowed to persist for acetylation and generation of  AcPGP to occur, which is pertinent given that we have 
previously demonstrated that cigarette smoke can both abrogate LTA4H peptidase activity and acetylate 
PGP (17, 18); however, ACE displays an important role in degrading any AcPGP that is generated.
A protective role for AcPGP in fibrosis. Given the role for ACE described within this study in regulating the 
AcPGP pathway, it is rational to question the significance of  this matrikine in the pathogenesis of  IPF. ACE 
expression has been demonstrated to be elevated in the lungs of  IPF patients (40–42), where it is thought to 
contribute to the development of  fibrosis through effects of  AngII on myofibroblasts and TGF-β signaling 
or through degradation of  the antifibrotic peptide AcSDKP (43). In keeping with previous studies, our own 
cohort of  IPF patients exhibited elevated BALF levels of  ACE relative to COPD patients (Figure 4 and Table 
1). Accordingly, PGP and AcPGP were both completely undetectable in the BALF of any of  these IPF 
patients when assessed by mass spectrometry (data not shown). We have previously demonstrated that smok-
ers and COPD patients present with substantial quantities of  PGP/AcPGP (21–24) that supports their per-
sistent airway inflammation and pathology, and intriguingly, BALF ACE levels in these patients tended to be 
lower than that observed in control individuals, though this failed to reach statistical significance (Figure 4).
To further explore the ACE-AcPGP axis in the pathogenesis of  IPF, we utilized the bleomycin 
mouse model that displays some of  the features of  human disease. In the bleomycin mouse model, there 
is an initial phase of  acute pulmonary inflammation, followed after several days by fibroproliferation 
and collagen deposition (44, 45). We sacrificed mice 1, 2, and 3 weeks after intratracheal (i.t.) bleomycin 
exposure and assayed BALF for PGP and AcPGP. In keeping with the IPF patients, bleomycin-exposed 
mouse BALF contained no PGP or AcPGP at any time point (data not shown). The AcPGP-degrad-
ing capacity of  bleomycin-exposed mice was subsequently assessed at each time point. BALF AcPGP 
degrading capacity was significantly greater than control mice 1 and 2 weeks after bleomycin exposure, 
BALF ACE protein levels and BALF albumin levels (determined by ELISA). (F–H) Balb/c mice were administered 1 μg MIP-2 i.n. and culled after 6 hours. 
BALF AcPGP–degrading activity was assessed by mass spectrometry (F) and ACE protein levels by ELISA (G). (H) Correlation between BALF ACE protein 
levels and BALF albumin levels (determined by ELISA). (I and J) Lta4h–/–
 
mice and littermate controls were administered 10 μg LPS i.n. and 2 mg captopril/
PBS control i.p. Mice were culled after 24 hours, and levels of PGP (I) and AcPGP (J) in BALF were assessed by mass spectrometry. Experiments are from 4 
(F and G) or 5 (A–D, I and J) mice/group and representative of 2 experiments. Spearman correlation (E and H) is representative of 2 experiments, each with 
at least 4 mice per group. Results depicted as mean ± SEM. *P < 0.05 or **P < 0.01 using Mann–Whitney statistical test (C and H) or Kruskal-Wallis with 
Dunn’s post test (G). Spearman correlation from 2 experiments with at least 5 mice per group.
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before declining modestly by week 3, suggesting that this peptidase activity is 
maximal during acute repair (Figure 5A). In this early inflammatory phase of  the 
bleomycin model, BALF AcPGP–degrading activity (Figure 5B) and ACE pro-
tein levels (Figure 5C) reassuringly demonstrated a comparable augmentation. To 
confirm that ACE was the enzyme degrading AcPGP in the bleomycin model, 
we demonstrated that addition of  captopril to BALF from bleomycin-exposed 
mice completely abolished its capacity to degrade AcPGP (Figure 5D). The aug-
mented BALF ACE levels observed in bleomycin-exposed mice may reflect an 
enhanced influx from the vascular compartment, as seen in an acute inflamma-
tory model, but both macrophages and myofibroblasts have been reported as a potential source of  this 
enzyme in fibrosis (46). Accordingly, macrophages were markedly augmented in BALF 1 week after 
bleomycin exposure (Figure 5E), in keeping with the peak ACE levels at this time point.
Given the pathological role of  ACE ascribed to the development of  IPF, we questioned whether 
the robust AcPGP degradation observed could paradoxically be pathological in the setting of  IPF. To 
test this hypothesis, AcPGP was administered i.t. daily for 14 days (starting at day 7 after bleomycin to 
coincide with the onset of  repair) to the lungs of  bleomycin-exposed mice at 2 different doses (250 μg 
or 125 μg), with mice being euthanized at day 21 (Figure 6A). Strikingly, the administration of  250 μg 
AcPGP per day almost completely prevented bleomycin-induced pulmonary fibrosis, with 125 μg per 
day also proving significantly effective (Figure 6, B–H). These histological findings of  reduced fibrosis 
were confirmed by whole lung hydroxyproline measurements, which were also strikingly reduced in 
bleomycin-treated animals (Figure 6I). As a point of  note and in keeping with an improved health 
status, bleomycin-exposed, AcPGP-treated mice also failed to lose weight, while PBS-treated mice lost 
weight as expected (24% ± 5% for PBS vs. 1.3% ± 1.2% for AcPGP; mean ± SEM). To assess the 
relative potencies of  AcPGP and PGP, bleomycin-exposed mice were subsequently treated with 250 
μg AcPGP, PGP, or control peptide PGG for 2 weeks starting at day 7 (Figure 7A). Administration 
of  AcPGP again largely prevented the development of  pulmonary fibrosis, with PGP being slightly 
less effective and PGG being completely ineffective (Figure 7, B–I). Again, histological findings were 
reflected by whole-lung hydroxyproline measurements (Figure 7J). These data indicate that the antifi-
brotic effect is mediated by the PGP tripeptide with N-terminal acetylation conferring greater potency, 
as previously reported with neutrophil chemotaxis (19). PGP may also be less effective in vivo, as it is 
rapidly degraded in the lung by LTA4H, whereas AcPGP is not (17).
Figure 4. ACE is elevated in BALF of IPF patients. BALF ACE levels in human subjects with 
IPF (n = 10) or COPD (n = 17) and healthy controls (n = 17) were determined by ELISA. Results 
depicted as mean ± SEM. *P < 0.05 using unpaired t test.
Table 1. Clinical features of patients with IPF and COPD and healthy subjects
Characteristic IPF COPD Control
n 10 17 17
Age (y) 66 (56–80) 62 (52–76) 53 (41–74)
Female sex 3 (30) 4 (24) 9 (53)
African American race 0 3 (18) 11 (65)
Current smoker 0 10 (59) 6 (35)
FEV1 % predicted 90 (62–127) 55 (36–80) 97 (81–124)
FVC % predicted 80 (51–116) 78 (57–91) 97 (82–140)
FEV1/FVC 0.86 (0.73–0.88) 0.56 (0.36–0.69) 0.77 (0.7–0.88)
TLC % predicted 67 (43–97)   
DLCO % predicted 52.5 (37–97)   
Emphysema seen on CT  13 (76) 0
Data presented as n (%) or median (range).
IPF, idiopathic pulmonary fibrosis; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; TLC, total 
lung capacity; DLCO, diffusing capacity of lung for carbon monoxide.
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Finally, we looked to directly ascertain 
whether the pathological role attributed to 
ACE in the development of fibrosis was specif-
ically a consequence of its ability to efficiently 
degrade AcPGP. Therefore, bleomycin-treated 
mice were administered the ACE inhibitor cap-
topril in their drinking water (starting 2 days 
prior to bleomycin exposure) with or without 
AcPGP antagonist arginine-threonine-argi-
nine (RTR) (47) (Figure 8A). Bleomycin-treat-
ed mice administered captopril were largely 
protected from development of fibrosis (Fig-
ure 8, B–J), with a significant reduction in lung 
hydroxyproline content (Figure 8K). However, 
the protective effect of captopril was lost when 
mice were concomitantly administered RTR 
(Figure 8), clearly demonstrating that protec-
tion afforded by ACE inhibition is attributable 
to AcPGP accumulation.
Discussion
We have previously demonstrated that the enzyme LTA4H is able to potently degrade the neutrophil 
chemoattractant PGP to ensure the efficient resolution of  inflammation (17) and that this system is 
perturbed in chronic lung diseases, enabling PGP accumulation and persistent neutrophilia (17, 21). 
However, the acetylated variant AcPGP is completely protected from LTA4H-mediated degradation 
(17). Accordingly, it is clear that the acetylation process is a critical event in defining bioavailability 
and pathogenesis of  this matrikine, with an abundance of  AcPGP observed in COPD and CF (14, 
15, 21–24). In this study, we identify a potentially novel pathway by which AcPGP can be degraded 
through an action of  the enzyme ACE. We demonstrate that pulmonary ACE is elevated during epi-
sodes of  acute inflammation, likely as a consequence of  enhanced vascular permeability, to ensure 
the efficient degradation of  AcPGP. Conversely, we anticipate that this pathway may be aberrant in 
COPD, enabling the accumulation of  AcPGP in this disease. Surprisingly, we subsequently identify a 
protective role for AcPGP in limiting pulmonary fibrosis, and we demonstrate the pathogenic function 
attributed to ACE in fibrosis to be a consequence of  overzealous AcPGP degradation. Thus, AcPGP 
can seemingly have very divergent roles: pathogenic in its capacity to drive neutrophilic inflammation 
and ECM degradation in the context of  COPD, but protective in its capacity to limit fibrotic lung dis-
ease observed in IPF. Thus, we hypothesize that while COPD and IPF may be diseases with similar 
etiologies, they ultimately manifest as very different pathologies as a consequence of  disparate pertur-
bations of  the AcPGP-ACE axis.
Figure 5. ACE is elevated in BALF following bleo-
mycin exposure to promote AcPGP degradation. 
(A) C57BL/6 mice were administered bleomycin i.t. 
and culled after 1, 2, and 3 weeks. BALF was incu-
bated with AcPGP and degradation assessed after 
24 hours by mass spectrometry. (B–E) C57BL/6 
mice were administered bleomycin i.t. and culled 
after 3 and 7 days. BALF AcPGP–degrading activity 
was assessed by mass spectrometry (B) and ACE 
protein levels by ELISA (C). BALF AcPGP–degrad-
ing activity was assessed with and without prein-
cubation with 1 μM captopril (D). (E) Macrophages 
and PMNs were enumerated in BALF 3 and 7 days 
after bleomycin exposure. Experiments are from 
4 mice/group. Results depicted as mean ± SEM. 
*P < 0.05 and **P < 0.01 using Mann–Whitney 
statistical test.
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Figure 6. AcPGP inhibits bleomycin-induced pulmonary fibrosis. C57BL/6 mice were administered bleomycin i.t. followed after a week by daily i.t. 
administrations of 125 μg or 250 μg AcPGP per mouse or PBS for 2 weeks (A). Representative H&E stained lung sections (B–G) and quantification of 
the fibrosis using the Ashcroft scoring system (H). Images are 20× and 200×, as indicated; scale bars: 500 μM. (I) Total lung hydroxyproline measure-
ments. Experiments are from at least 5 mice/group and representative of 2 independent experiments. Results depicted as mean ± SEM. *P < 0.05 or 
**P < 0.01 using Kruskal-Wallis with Dunn’s post test.
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The renin-angiotensin system (RAS) 
controls blood pressure and renal homeo-
stasis (48), with the enzyme ACE func-
tioning as the distal enzyme in a cas-
cade that generates AngII from AngI 
(49). AngII is a powerful vasoconstrictor 
and, thus, is critical in the regulation of  
blood pressure (50). While ACE clas-
sically functions to generate AngII, it 
is acknowledged to be a promiscuous 
enzyme with the capacity to act on a vari-
ety of  natural substrates, and it possesses 
physiological roles beyond its capacity to 
modulate blood pressure (51). Of  note, it 
has been demonstrated that ACE has the 
capacity to degrade AcSDKP, a tetrapep-
tide that has been shown to be capable 
of  suppressing fibrosis (52–55). We now 
identify AcPGP as a peptide substrate 
for ACE and highlight a capacity for the 
AcPGP-ACE axis in differentially regu-
lating inflammation and fibrosis.
ACE is tethered to the luminal side 
of  the endothelium, with circulating 
plasma ACE derived from proteolyt-
ic cleavage (56), rationalizing the high 
levels of  AcPGP-degrading activity and 
ACE seen in our studies in the blood 
and highly vascularized organs such as 
the lungs. To degrade ECM collagen–
derived AcPGP within the lung, ACE 
must be freely available in an extracellular environment. We have presented evidence suggesting that 
BALF ACE is elevated during episodes of  inflammation as a consequence of  increased vascular per-
meability and an influx of  plasma enzyme. Given that ACE is expressed by multiple cell types that 
are prevalent within the fibrotic lung, we cannot, however, disregard the possibility that there is also a 
localized release of  ACE from resident and infiltrating cells. ACE exists as a single polypeptide chain, 
with 2 homologous but independent N- and C-terminal catalytic domains (57). Both catalytic sites of  
ACE can hydrolyze AngI, but only the N-domain site can degrade atypical substrates such as AcS-
DKP (53, 58–60). Captopril has a higher affinity for the N-domain site of  ACE (61) and accordingly 
inhibits hydrolysis of  AcSDKP with lower inhibitory constant (Ki) than AngI (62). Since captopril also 
inhibited hydrolysis of  AcPGP more than an AngI-like substrate, AcPGP cleavage is also likely to be 
restricted to the N-domain.
Figure 7. Efficacy of peptide analogs of 
AcPGP against fibrosis. C57BL/6 mice were 
administered bleomycin i.t. followed after 
a week by daily i.t. administrations of 250 
μg AcPGP, PGP, PGG, or PBS for 2 weeks (A). 
Representative H&E-stained lung sections 
(B–I). Images are 20× and 200×; scale bars: 
500 μM. (J) Total lung hydroxyproline mea-
surements. Experiments are from at least 5 
mice/group and representative of 2 indepen-
dent experiments. Results depicted as mean 
± SEM. **P < 0.01 using Kruskal-Wallis with 
Dunn’s post test.
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Striking similarities exist between the LTA4H-PGP axis we have previously described (17) and the 
ACE-AcPGP axis described in this study. Both LTA4H and ACE are dual-functioning enzymes with com-
plex roles in health and disease. LTA4H classically functions to generate the proinflammatory lipid medi-
ator LTB4, a function seemingly at odds with its antiinflammatory PGP-degrading activity (17). ACE is 
a truly promiscuous enzyme that has multiple peptide substrates with pleiotropic physiological functions 
(51), though degradation of  AcPGP is the first truly antiinflammatory activity ascribed to this enzyme. In 
this study, we demonstrate that PGP is normally degraded by LTA4H and that PGP accumulation (and 
hence failure of  the LTA4H system) is a requisite for conversion to AcPGP, with ACE subsequently func-
tioning to degrade any of  the acetylated variant that is generated. Thus, it would appear that 2 enzymes act 
Figure 8. A PGP antagonist abrogates the antifibrotic effects of captopril. C57BL/6 mice were provided with water or water supplemented with 
captopril and administered bleomycin i.t., followed a week later by i.t. administrations of 50 μg RTR or PBS 3 times a week for 2 weeks (A). Represen-
tative H&E-stained lung sections (B–I) and quantification of the fibrosis using the Ashcroft scoring system (J). Images are 20× and 200×. (K) Total lung 
hydroxyproline measurements. Experiments are from 3–5 mice/group and representative of 2 independent experiments. Results depicted as mean ± 
SEM. *P < 0.05 using Kruskal-Wallis with Dunn’s post test.
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in tandem during episodes of  acute inflammation to ensure that no PGP or AcPGP are allowed to persist 
and that neutrophilia is resolved. AcPGP has recently been demonstrated to function to promote vascular 
permeability via direct interaction with endothelial cells (63), and thus, the peptide can itself  indirectly pro-
mote its own degradation through increasing availability of  tissue ACE. Given the role ascribed to AcPGP 
in this study in limiting fibrosis, it should be considered that fibrosis is actually a repair process gone wrong. 
Under physiological conditions, it may be that AcPGP functions to limit any repair during early/ongoing 
inflammation, but as AcPGP is degraded by ACE and inflammation resolved, a repair process is initiated.
Levels of  PGP/AcPGP are elevated in murine cigarette-smoke models of  emphysema (21, 64) and 
clinical samples from smokers and COPD patients (21–24), wherein the accumulation of  peptide can drive 
neutrophil persistence and protease imbalance. Given the role ascribed to AcPGP/PGP in this study in lim-
iting fibrosis, it is plausible that accumulations of  these peptides in COPD patients may not only perpetuate 
inflammation, but also prevent reparative processes from taking place. We have previously demonstrated 
that reactive aldehydes within cigarette smoke are able to inhibit the PGP-degrading activity of  LTA4H, 
rationalizing the accumulation of  PGP in COPD patients and murine models (17, 21). Furthermore, the 
same reactive aldehydes are also capable of  acetylating PGP (to AcPGP) and, thus, protecting it from 
LTA4H-mediated degradation (18). It is feasible that the ACE pathway is also aberrant in COPD, and from 
our cohort of  patients, there is the suggestion that BALF ACE levels are reduced in COPD patients relative 
to healthy controls and IPF. Previous studies into the effect of  cigarette smoke on ACE levels/activity 
have been inconsistent and conflicting, though a reduction in ACE levels (65) and activity (66) have been 
reported in smokers relative to nonsmokers, with activity increased again by smoking cessation.
Increasingly, it is apparent that elevated ACE levels are associated with aberrant repair and fibrosis, 
though the mechanisms defining the pathogenesis are poorly defined. Increased ACE expression in pulmo-
nary granulomas in sarcoidosis has long been recognized (67), and elevations in ACE have been reported 
in IPF (40–42). The classical product of  ACE, AngII, has been suggested to play a role in tissue fibrosis 
through upregulation of  collagen gene expression in lung fibroblasts and apoptosis of  alveolar epithelial 
cells (40, 68). Accordingly, some studies have reported a partial amelioration of  bleomycin-induced pulmo-
nary fibrosis following administration of  angiotensin II receptor type 1 receptor antagonists such as losar-
tan (69–71). However, other studies have failed to confirm these protective effects of  AngII receptor antago-
nism (72), and it is increasingly anticipated that other activities of  ACE may be integral in defining fibrosis. 
AcSDKP has been suggested to be antifibrotic, and thus, the pathological role ascribed to ACE could be 
attributable to its capacity to degrade this peptide. Mice deficient in the N-domain of  ACE were protected 
from bleomycin-induced lung fibrosis. Though AcSDKP could not be detected in the lungs of  the mice, 
the protective effect was ascribed to preservation of  this peptide (43). To support this notion, inhibition of  
the enzyme PE that is critical to the generation of  AcSDKP restored the fibrotic phenotype (73). However, 
PE is also critical for PGP generation, and hence, the aforementioned protective phenotype of  ACE N-do-
main–KO mice could be attributed to a failure of  ACE to degrade AcPGP. Accordingly, we have demon-
strated that administration of  AcPGP to the lungs of  mice dramatically and dose-dependently reduced 
collagen accumulation and fibrosis. Furthermore, we demonstrated that the capacity of  the ACE inhibitor, 
captopril, to ameliorate bleomycin-induced pulmonary fibrosis was entirely dependent on AcPGP accumu-
lation, since protection was abolished by the AcPGP antagonist RTR. The mechanism whereby AcPGP 
prevents fibrosis in vivo is yet to be defined but could be due to proteolytic degradation of  the ECM, given 
the capacity of  PGP accumulation to drive protease imbalance in the lung (25). Alternatively, AcPGP may 
possess unappreciated roles in defining wound repair and fibrosis by modulating processes such epithelial 
cell apoptosis, fibroblast recruitment/differentiation, collagen synthesis/deposition, or collagen removal 
by macrophages. Elucidating this pathway would provide additional ways of  influencing the ACE-AcPGP 
axis and suggest therapeutic approaches for IPF.
While previous studies have largely ascribed a predominantly pathological role to PGP/AcPGP in 
diseases such as COPD and CF, it now seems likely that this peptide in moderation serves a beneficial role 
in limiting excessive collagen deposition. COPD and IPF are thought to arise from common etiologies and 
yet manifest with quite disparate disease pathologies. Is it feasible that divergences in the ACE-AcPGP 
axis define the relative progression of  disease? If  PGP/AcPGP is allowed to persist, as in COPD, then 
it can drive a vicious cycle of  neutrophilic inflammation and protease imbalance, while simultaneously 
preventing repair. Conversely, if  PGP/AcPGP are degraded too efficiently, as may be the case in IPF, then 
no signal is present to limit collagen deposition; hence, fibrosis ensues. Levels of  PGP/AcPGP generation 
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and degradation will ultimately be key in defining this balance, which in turn are seemingly dictated by 
genetic and environmental influences. In this manner, differences in ACE expression and activity between 
individuals could explain differing susceptibilities to smoking-induced lung diseases and phenotypes via 
modulating levels of  AcPGP.
Methods
Mice. Six- to 8-week-old female BALB/c mice were purchased from Harlan Laboratories. Six- to 8-week-
old female C57BL/6 mice were purchased from The Jackson Laboratory. Lta4h–/– mice and littermate 
controls were on a 129/S6 background and bred in house at Imperial College London, with female 6- to 
8-week-old mice utilized in experiments. ACE 1 mice (null for ACE) (74) and ACE 14/14 mice (null for 
somatic ACE) (provided by Ken Bernstein, Cedars-Sinai Medical Center, Los Angeles, CA, USA) and 
respective littermate controls were bred in house at Sinai-Cedars Medical Centre, with plasma from 11- to 
20-week-old female and male mice utilized in experiments. All mice were kept in specified pathogen-free 
conditions and provided autoclaved food, water, and bedding.
Lta4h–/– mice were genotyped by PCR on genomic DNA extracted using the Extract-N-Amp Tissue PCR 
Kit (MilliporeSigma). The WT expression of  LTA4H was detected by primers oIMR1720 (5′ - CGA ATC 
CAT GCT TAA AAT TGC - 3′) and oIMR1721 (5′ - GCG TTA CGA ACG TGA GAC AA - 3′) to yield a 
product size of  128 bp, and Lta4h–/– LTA4H was detected by primers oIMR6916 (5′ - CTT GGG TGG AGA 
GGC TAT TC - 3′) and  oIMR6917 (5′ - AGG TGA GAT GAC AGG AGA TC - 3′) to yield a product size 
of  280 bp. Amplification was achieved by PCR (94°C for 3 min > 35 × 2.5 min cycles [30 sec at 94°C > 60 sec 
at 60°C > 60 sec at 72°C] > 72°C for 2 min). Amplification fragments were visualized on agarose gels (2%).
Mouse challenge models. Balb/c mice were anesthetized with isoflourane and treated i.n. with 50 μg/kg 
recombinant murine MIP-2 (Peprotech) or 500 μg/kg LPS (ultrapure from E. coli K12 strain; InvivoGen), 
both in 50 μl PBS, and culled at times indicated in the text. In some experiments, Balb/c mice received 
250 mg/kg histamine (MilliporeSigma) i.v. in 200 μl PBS and were culled 30 minutes later. In other exper-
iments, Lta4h–/– mice and littermate controls were anesthetized with isoflourane and treated i.n. with 500 
μg/kg LPS in 50 μl PBS. These mice were also administered i.p. captopril (100 mg/kg; MilliporeSigma) or 
200 μl PBS (control) at the time of  LPS administration and 24 hours prior.
Bleomycin sulphate (MilliporeSigma) dissolved in 50 μl sterile saline was administered i.t. to C57BL/6 
mice at a dose of  1 U/kg. Control mice received saline. In some experiments, mice were also administered 
250 μg or 125 μg AcPGP/PGP (Bachem) dissolved in 50 μl PBS or PBS i.t. every day for 2 weeks starting a 
week after bleomycin exposure. In other experiments, mice were provided with drinking water supplement-
ed with captopril (500 mg/l; MilliporeSigma) starting 2 days prior to administration of  bleomycin, and 
were subsequently administered 50 μg RTR (Bachem) dissolved in 50 μl PBS or PBS i.t. 3 times per week 
for 2 weeks starting a week after bleomycin exposure.
Cell recovery and isolation. Mice were administered 150 mg/kg pentobarbital and exsanguinated via the 
femoral artery. Serum was isolated by centrifugation for 8 minutes at 5,000 g and frozen at –80°C until 
required. To obtain plasma, blood was collected via cardiac puncture and diluted 10-fold into Buffered 
Citrate (60 mM sodium citrate/40 mM citric acid), and then centrifuged 2 times at 800 g for 10 minutes 
with supernatant collected. To perform broncholaveolar lavage, the lungs were then inflated 5 times with 
1.5 ml PBS via an i.t. cannula, and the resulting BALF was centrifuged once at 400 g and the supernatant 
stored at –80°C. Right superior lung lobes, spleen, liver lobe, and a segment of  the small intestine dissected 
from naive Balb/c mice were snap frozen at the time of  harvest. These tissues were subsequently homoge-
nized in PBS at a concentration of  50 mg/ml. Homogenates were centrifuged at 800 g for 10 minutes, and 
supernatant was collected for downstream analysis.
Human BALF. BALF from human subjects with COPD were remnants obtained from a previous clinical 
trial (75). Subjects (Table 1) aged 40–80 years, smokers and nonsmokers, were categorized as COPD or con-
trols based on the presence or absence of  airflow obstruction (FEV1/FVC below the lower limit of  normal for 
age, race, sex, and height). A minimum of 10 pack years of  tobacco use was required for patients with COPD. 
COPD patients were on inhaled bronchodilators and/or corticosteroids only. Exclusion criteria were asthma, 
bronchiectasis, or other lung disease and any change in respiratory medications or respiratory illness in the 
month prior to enrollment. BALF from subjects with IPF were remnants from specimens obtained for clinical 
purposes. IPF (Table 1) was defined as an appropriate clinical presentation with usual interstitial pneumonia 
(UIP) seen on high-resolution chest CT scans that were absent other causes of  interstitial lung disease (76). 
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In some cases, UIP was confirmed by surgical lung biopsy. Subjects with IPF had stable disease and were not 
taking oral corticosteroids, immune suppressants, perfenidone, or nintedanib.
Assessment of  fibrosis in bleomycin-exposed mice. At the end of  the treatment period, mice were euthanized 
and lungs excised and inflated with 4% paraformaldehyde in PBS for histochemical analysis by H&E. The 
Ashcroft scoring system was used to assess the pulmonary fibrotic changes in lung tissue sections (77). Two 
independent and blinded observers determined the Ashcroft fibrosis score for each experimental group 
from at least 3 individual experimental mice of  each group. Whole-lung collagen levels were determined 
by assessment of  lung hydroxyproline. The harvested lungs were hydrolyzed in 6 mol/l HCl at 110°C for 
24 hours, and the amount of  hydroxyproline in the lung acid–hydrolysates was determined by colorimetric 
assay, as previously described (78).
AcPGP degradation experiments. BALF (neat), serum (diluted 1/10 in PBS), tissue homogenate (diluted 
1/10 in PBS), or recombinant porcine ACE and prolidase (at concentrations defined in the text; Milli-
poreSigma) were incubated with 1 μg/ml (BALF) or 100 μg/ml (all other tissues and recombinant proteins) 
AcPGP at 37°C 5% CO2 for varying periods of  time (as defined in the Figure 1–3 and 5 legends). Concen-
trations of  AcPGP remaining were subsequently quantified by liquid chromatography–electrospray ioniza-
tion-tandem mass spectrometry (ESI-LC/MS/MS; as discussed below) by comparison with AcPGP stan-
dards. The percentage of  peptide degraded was determined relative to control samples of  AcPGP alone. In 
some instances, AcPGP degradation was expressed as μg peptide degraded/mg of  total tissue protein or 
per ml of  biological fluid. AcPGP degradation was also assessed by measurement of  free proline released 
and its ensuing reaction with ninhydrin (as discussed below). In some experiments, serum was preincubat-
ed with EDTA, AEBSF, PMSF, E64, antipain (all 1 μM; MilliporeSigma), captopril, or enalopril (as con-
centrations defined in the text; MilliporeSigma) for 30 minutes at 3°C 5% CO2 prior to addition of  AcPGP.
ESI-LC/MS/MS for PGP detection. For peptide quantification in BALF, PGP, and AcPGP were mea-
sured using a MDS Sciex API-4000 spectrometer (Applied Biosystems) equipped with a Shimadzu HPLC. 
For peptide quantification from degradation experiments, AcPGP was measured using a Thermo Accela 
Pump and Autosampler coupled to a Thermo TSQ Quantum Access. HPLC was done using a 2.0 × 150 
mm Jupiter 4 μm Proteo column (Phenomenex) with (buffer A) 0.1% HCOOH and (buffer B) MeCN + 
0.1% HCOOH for 0–0.5 min 5% buffer B/95% buffer A, then increased over 0.5–2.5 min to 100% buffer 
B/0% buffer A. Background was removed by flushing with 100% isopropanol/0.1% formic acid. Positive 
electrospray mass transitions were at 270–70, 270–116, and 270–173 for PGP and 312–140 and 312–112 
of  AcPGP. Peak area was measured, and PGP/AcPGP peptide concentrations were calculated using a 
relative standard curve method, as previously described (12).
Measurement of  free proline. Aliquots from PGP degradation experiments were diluted 1:10 in PBS (to a 
final volume of  250 μl). Glacial acetic acid (250 μl) was then added, followed by 250 μl of  ninhydrin solu-
tion (25 mg/ml in acetic acid/6 M phosphoric acid; heated at 70°C to dissolve). The reaction mixture was 
heated at 100°C for 60 minutes and allowed to cool to room temperature, the proline containing fraction 
was extracted with 500 μl of  toluene, and optical density was measured at 520 nm.
ACE quantification. The levels of  ACE in BALF and tissues was measured by ELISA per the manufac-
turer’s directions (Duo Set; R&D Systems).
Albumin quantification. Suitably diluted mouse BALF was assessed for albumin (Bethyl Laboratories) by 
ELISA, following the manufacturer’s instructions.
Statistics. Mouse data were assessed for normal distribution using the Shapiro-Wilk normality test and 
found to be nonnormal. For comparison between 2 groups, statistical significance was calculated with a 
nonparametric Mann-Whitney test (2-sided). Group comparisons were performed using a nonparametric 
ANOVA test (Kruskal-Wallis), followed by a Dunn’s post test for multiple comparisons between groups. 
Details of  specific statistical test used for each experiment are described in respective figure legends. Results 
are depicted as mean ± SEM unless stated otherwise. Correlations were calculated using a Spearman’s 
Rank Correlation coefficient for nonparametric data. Assessment of  statistical significance of  ACE levels 
in human BALF was performed by a parametric unpaired t test. All P values of  ≤ 0.05 (*) and ≤ 0.01 (**) 
were considered significant and are referred to as such in the legends. Graph generation and statistical anal-
yses were performed using GraphPad Prism software (GraphPad Software Inc.).
Study approval. For animal experiments conducted at Imperial College London, research was carried out 
in accordance with the recommendations in the Guide for the Use of  Laboratory Animals of  Imperial Col-
lege London. All animal procedures and care conformed strictly to the UK Home Office Guidelines under 
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the Animals (Scientific Procedures) Act 1986, and the protocols were approved by the Home Office of  Great 
Britain. Animal experiments at the University of  Alabama at Birmingham were performed in accordance 
with the NIH guidelines for the IACUC. Plasma samples obtained from WT and ACE-KO animals followed 
protocols approved by the Cedars-Sinai IACUC. Human BALF samples were from a repository approved 
by the IRB of the University of  Alabama at Birmingham. All subjects provided written, informed consent.
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